We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
IDT Corporation | NYSE:IDT | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
1.00 | 2.81% | 36.54 | 36.60 | 35.60 | 35.72 | 65,439 | 00:46:58 |
CRANBURY, N.J., Feb. 8, 2017 /PRNewswire/ -- Cornerstone Pharmaceuticals, Inc. today announced a number of additions to its Scientific and Medical Advisory Boards, continuing the company's recent momentum of growth in its management team and governing and advisory bodies. Members of Cornerstone's Scientific and Medical Advisory Boards are highly regarded researchers and physicians within the fields of oncology, hematology and lymphoma. They will help strengthen Cornerstone's drug development and commercialization capabilities at a pivotal time in the company's lifecycle, and provide guidance on the company's clinical trial strategy.
"Innovation in oncology drug development requires a multidisciplinary team comprised of experts in the scientific and medical fields. We have assembled unparalleled boards of scientific and medical advisors who will work with Cornerstone to help revolutionize anticancer treatment among our prime treatment targets: pancreatic cancer, acute myeloid leukemia and lymphoma," said Howard Jonas, Chairman of the Board of Cornerstone. "The combination of skills among the world-renowned cell biologists, oncology researchers and clinical oncologists on the advisory boards will further enhance Cornerstone's ability to develop and advance our cutting-edge R&D pipeline."
Chi Van Dang, M.D., Ph.D., the incoming Chair of the Scientific and Medical Advisory Boards said, "The addition of such highly regarded and experienced scientific and medical advisors, better positions Cornerstone as an incoming leader in the growing field of metabolic cancer therapy. I am excited to have the opportunity to work alongside such uniquely qualified colleagues."
Chair of the Scientific and Medical Advisory Boards
Chi Van Dang, M.D., Ph.D.: Director of the Abramson Cancer Center of the University of Pennsylvania until July 1, 2017, when he will become Scientific Director of the Ludwig Institute for Cancer Research. Dr. Dang is considered by many to be the world's leading authority on cancer metabolism. Dr. Dang is also serving on Cornerstone's Board of Directors.
Scientific Advisory Board
Medical Advisory Board
Pancreatic Cancer Advisors
Acute Myeloid Leukemia Advisors
Lymphoma Advisors
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit: www.cornerstonepharma.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Contact: |
Jacob Jonas |
Public Relations, Cornerstone Pharmaceuticals, Inc. | |
jacob@cornerstonepharma.com | |
Kara Golub | |
JFK Communications, Inc. | |
609-456-0822 | |
kgolub@jfkhealth.com |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-inc-announces-the-addition-of-world-renowned-experts-to-scientific-and-medical-advisory-boards-300404070.html
SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright 2017 PR Newswire
1 Year IDT Chart |
1 Month IDT Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions